Pulmonx Co. (NASDAQ:LUNG) Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. cut its stake in Pulmonx Co. (NASDAQ:LUNG) by 27.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 768,430 shares of the company’s stock after selling 287,092 shares during the period. JPMorgan Chase & Co. owned 1.95% of Pulmonx worth $5,218,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in LUNG. 272 Capital LP acquired a new stake in shares of Pulmonx in the 3rd quarter valued at about $48,000. R Squared Ltd acquired a new position in Pulmonx in the fourth quarter worth $46,000. SG Americas Securities LLC increased its stake in Pulmonx by 27.0% during the fourth quarter. SG Americas Securities LLC now owns 15,555 shares of the company’s stock valued at $106,000 after purchasing an additional 3,310 shares during the last quarter. American Century Companies Inc. grew its position in shares of Pulmonx by 8.8% during the 4th quarter. American Century Companies Inc. now owns 34,738 shares of the company’s stock valued at $236,000 after buying an additional 2,810 shares during the last quarter. Finally, Rhumbline Advisers raised its stake in Pulmonx by 4.9% during the fourth quarter. Rhumbline Advisers now owns 53,503 shares of the company’s stock worth $363,000 after acquiring an additional 2,488 shares during the period. 91.04% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Morgan Stanley started coverage on Pulmonx in a research report on Monday, March 10th. They set an “equal weight” rating for the company. D. Boral Capital started coverage on shares of Pulmonx in a research note on Monday, March 10th. They set a “buy” rating and a $17.00 target price for the company. Citigroup initiated coverage on shares of Pulmonx in a research note on Monday, March 10th. They issued a “buy” rating on the stock. Finally, Jefferies Financial Group began coverage on Pulmonx in a report on Monday, March 10th. They issued a “buy” rating for the company. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Pulmonx currently has a consensus rating of “Moderate Buy” and an average target price of $12.75.

Insider Buying and Selling at Pulmonx

In other news, insider Geoffrey Beran Rose sold 5,779 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $7.13, for a total transaction of $41,204.27. Following the transaction, the insider now directly owns 285,278 shares in the company, valued at $2,034,032.14. The trade was a 1.99 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Glendon E. French III sold 55,453 shares of the stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $8.28, for a total value of $459,150.84. Following the sale, the director now owns 1,011,974 shares of the company’s stock, valued at approximately $8,379,144.72. This represents a 5.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 145,660 shares of company stock valued at $1,128,484 in the last three months. 5.70% of the stock is currently owned by company insiders.

Pulmonx Trading Down 5.6 %

Shares of LUNG stock opened at $4.52 on Friday. Pulmonx Co. has a fifty-two week low of $4.49 and a fifty-two week high of $10.01. The company has a quick ratio of 6.77, a current ratio of 7.70 and a debt-to-equity ratio of 0.40. The stock has a 50-day simple moving average of $7.03 and a 200 day simple moving average of $6.68. The stock has a market capitalization of $181.92 million, a P/E ratio of -3.14 and a beta of 0.61.

Pulmonx (NASDAQ:LUNG) last announced its earnings results on Wednesday, February 19th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.12. The business had revenue of $23.77 million during the quarter, compared to the consensus estimate of $22.29 million. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. On average, sell-side analysts expect that Pulmonx Co. will post -1.55 earnings per share for the current fiscal year.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.